Marshall Wace’s Prime Medicine PRME Stock Holding History

Marshall Wace’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$800K	Buy	216,841 +74,884	+53%	+$249K	﹤0.01%	2310
2026 Q1	$494K	Buy	+141,957	New	+$540K	﹤0.01%	2463

Other funds holding PRME

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Marshall Wace's PRME Position: Q2 2026 in Review

Marshall Wace increased its Prime Medicine (PRME) stake by 53% in Q2 2026, buying an estimated $249K and bringing the position to 216,841 shares worth $800K. The position accounts for ﹤0.01% of the portfolio, ranked #2310.

Marshall Wace first reported a position in PRME in Q1 2026 and has held it in 2 quarters since. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

Marshall Wace held 216,841 shares of Prime Medicine worth $800K as of Q2 2026.
Marshall Wace bought 74,884 Prime Medicine shares in Q2 2026, an estimated $249K.
Prime Medicine made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2310 holding.
Marshall Wace first reported a position in Prime Medicine in Q1 2026 and has held it in 2 quarters since.
187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.